Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

Baraliakos, Xenofon; Gossec, Laure; Pournara, Effie; Jeka, Sławomir; Mera, Antonio; D’Angelo, Salvatore; Schulz, Barbara; Rissler, Michael; Nagar, Kriti; Perella, Chiara; C. Coates, Laura

doi:10.1136/annrheumdis-2020-218808

Public

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial

Published in Annals of the Rheumatic Diseases • Dec 22, 2020

Authors:

Xenofon Baraliakos

Laure Gossec

Effie Pournara

Abstract

OBJECTIVES: MAXIMISE (Managing AXIal Manifestations in psorIatic arthritis with SEcukinumab) trial was designed to evaluate the efficacy of secukinumab in the management of axial manifestations of psoriatic arthritis (PsA). METHODS: This phase 3b, double-blind, placebo-controlled, multi-centre 52-we...

Subject

Secukinumab

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!